Novartis's consumer health unit has decided to recall some of its products in the United States with an aim to serve the consumers in the market with an improved quality standard product.

The results of a large-scale clinical trial have revealed that the survival of older breast cancer patients can be extended with the use of the Novartis-manufactured bone drug Zometa, which seemingly does nothing to improve disease-free survival among the younger patients of the disease!

A new clinical research has sown that Amgen's new osteoporosis drug denosumab delayed bone problems in patients with advanced breast cancer five months more than Novartis's Zometa.

The long term trial data showed that Amgen drug proved better by 18 percent at delaying first bone problem and 22 percent better in time to first and subsequent event in women whose breast cancer has spread to the bone.

In a move that would help boost revenues at drug delivery group Vectura, the company’s licensing partner Novartis has decided to continue clinical trials on one of the former’s drugs NVA237, being tested to treat chronic obstructive pulmonary disease.

U. S. Food and Drug Administration has commended Novartis' meningococcal vaccine Menveo and granted priority review for its multiple sclerosis pill Gilenia.

As per the estimations of the analysts, both the products have immense potential and its yearly sales may reach $1bn mark in the next few years.

The company claims that Menveo can be given to people from different age groups.

Drug maker Novartis AG named Joe Jimenez, head of the company’s pharmaceuticals division, is reported to be appointed as chief executive officer.

He is a 1982 graduate from Stanford University, where he competed on the swimming team, in Palo Alto, California and fetched a master’s degree in business from the University of California at Berkeley.